Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.
about
Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytesDevelopment of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidateCurrent understanding of the mechanism of HPV infectionConcatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccinesVLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirusDurable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopesCapsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approachProduction of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific AntibodiesA pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2Role of CD8(+) T-cell immunity in influenza infection: potential use in future vaccine development.Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types.Papillomavirus prophylactic vaccines: established successes, new approaches.The role of furin in papillomavirus infection.Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodiesImmunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizingPerspectives for preventive and therapeutic HPV vaccines.HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responsesDeveloping vaccines against minor capsid antigen L2 to prevent papillomavirus infection.A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building.Strong inverse correlation between microRNA-125b and human papillomavirus DNA in productive infection.Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses.Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.Second-generation prophylactic HPV vaccines: successes and challenges.A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection.HPV vaccination for prevention of skin cancer.Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.Chitosan-Poly (I:C)-PADRE Based Nanoparticles as Delivery Vehicles for Synthetic Peptide VaccinesChimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)Targeting human papillomavirus genome replication for antiviral drug discoveryMurine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and speciesPhylogenetic considerations in designing a broadly protective multimeric L2 vaccineAdherence of non-O157 Shiga toxin-producing Escherichia coli to bovine recto-anal junction squamous epithelial cells appears to be mediated by mechanisms distinct from those used by O157.Influence of oxidation and multimerization on the immunogenicity of a thioredoxin-l2 prophylactic papillomavirus vaccineProgress and prospects for L2-based human papillomavirus vaccinesBroad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus.A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants.
P2860
Q21143868-ED9674EB-CD85-4571-990E-7B40EB6FEECAQ24288709-EF0EC4ED-9820-4F5C-A0F6-79CE19471A22Q24616134-1FFA4834-9040-4B03-AA38-73160A59996DQ28246307-A2E10780-8F68-4905-B3B4-D1BD534F9592Q28280059-F124D8B7-435D-4BE7-8509-29D4D120DCEBQ28603888-EABB86F9-B267-4D90-8F00-10812C09D3A8Q28607775-0E85CA17-072D-4A76-ACF7-6370A1DCA794Q28611356-F79FA61C-F726-4F4C-81B8-6AA5471A3F4AQ28741364-0D4E456D-AAA4-41C4-A59D-28EB09BAE09CQ30389274-58CA6457-52E9-414B-9B45-CC25AADE5DDAQ33569555-3A6D6B25-A67E-4DF3-AF39-91FD151F6B0AQ33572691-84CD7F76-A5B5-47C3-8260-C0DB7713C735Q33614425-F666BF7A-CFCD-44AF-8FED-B92184F740B3Q33693739-39C21BE2-7D1A-4A0B-9BF7-2C70A59B3645Q33780651-A9F551ED-7BC2-429F-91A9-775AFBA918D6Q33967341-8EBBBC72-2D64-47A1-A3F0-CCE90F1EAE52Q34011494-334EDF0C-5AB3-441D-A4ED-EC3CFBC28D91Q34335370-708CC287-7811-45DD-BA14-A2AD067B8AB6Q34455275-D943D087-13CE-4015-96EF-7E46B468DD5DQ34786808-BF12B25B-33BE-4909-8D17-D8766D747EB1Q34787042-FD0292A4-0460-408F-9553-B2724686A098Q34836445-1C2A03EC-EAEB-478A-8D94-55BDB170C596Q35042602-846F4095-6A7B-40ED-BFF5-73AAC2487280Q35095954-31455DF7-AECB-4162-9B65-2479772E5583Q35196119-7BDF08DC-C4E2-4319-A1B6-42769857F37BQ35541886-A1669937-84DA-4DF7-A2AB-AB905773E95AQ35599310-D015F387-771F-41C0-AE9B-50A03A83ABAFQ35887782-9B885FFB-4108-4780-9C68-F2BF4AC20C3AQ35918834-33194D3C-700C-4F78-911D-691FDDD6E1A5Q36101913-18C878B7-2901-4E64-ACC0-397A21A86704Q36240497-3A4D4325-996D-4940-9EF0-0B99C9D03C93Q36315302-E51A5380-16E7-4EAE-8E7A-8AC840B5BEADQ36554810-B541DF71-52C1-41C7-BAAE-FEA0CE8302D4Q36827128-E8739B10-4170-45B3-9712-5FFDB475A6C3Q36865822-C9EC5BFD-EFC3-47A9-A835-75014E44B532Q36970255-DC1D9DB5-29D3-4896-AADA-AF79998E984BQ37014047-C7B0E81A-F768-490F-9AFC-EC0DF3EC9B5DQ37073299-9506FD79-4A5C-4E12-B8BD-3236DD6F8AFFQ37099713-D1A5349A-3F9A-402C-8FAF-56EE8F1C0785Q37202927-A8E4DACA-3268-4ABD-AFB6-D2A69FAA1859
P2860
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Protection against heterologou ...... ss-neutralizing epitope of L2.
@ast
Protection against heterologou ...... ss-neutralizing epitope of L2.
@en
type
label
Protection against heterologou ...... ss-neutralizing epitope of L2.
@ast
Protection against heterologou ...... ss-neutralizing epitope of L2.
@en
prefLabel
Protection against heterologou ...... ss-neutralizing epitope of L2.
@ast
Protection against heterologou ...... ss-neutralizing epitope of L2.
@en
P2093
P2860
P356
P1476
Protection against heterologou ...... ss-neutralizing epitope of L2.
@en
P2093
Balasubramanyam Karanam
Hannah H Alphs
Jeffrey N Roberts
John T Schiller
Ratish Gambhira
Richard B S Roden
Subhashini Jagu
Weiguang Zeng
P2860
P304
P356
10.1073/PNAS.0800868105
P407
P577
2008-04-14T00:00:00Z